These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24384592)

  • 1. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM; Celum C; Mugo N; Campbell JD; Donnell D; Bukusi E; Mujugira A; Tappero J; Kahle EM; Thomas KK; Baeten JM;
    AIDS; 2013 Aug; 27(13):2155-60. PubMed ID: 24384592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM; Donnell D; Ndase P; Mugo NR; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kakia A; Odoyo J; Mucunguzi A; Nakku-Joloba E; Twesigye R; Ngure K; Apaka C; Tamooh H; Gabona F; Mujugira A; Panteleeff D; Thomas KK; Kidoguchi L; Krows M; Revall J; Morrison S; Haugen H; Emmanuel-Ogier M; Ondrejcek L; Coombs RW; Frenkel L; Hendrix C; Bumpus NN; Bangsberg D; Haberer JE; Stevens WS; Lingappa JR; Celum C;
    N Engl J Med; 2012 Aug; 367(5):399-410. PubMed ID: 22784037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
    Were EO; Heffron R; Mugo NR; Celum C; Mujugira A; Bukusi EA; Baeten JM;
    AIDS; 2014 Aug; 28(13):1977-82. PubMed ID: 25259704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
    N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
    Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
    J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antiretroviral chemoprophylaxis: current status.
    Baeten J; Celum C
    Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.